Heart failure & cardiomyopathies
β-Blocker Withdrawal and Functional Capacity Improvement in Patients With Heart Failure With Preserved Ejection Fraction
Authors' conclusion
In this study, results showed that in patients with HFpEF and chronotropic incompetence receiving treatment with β-blocker, lower iLVESV may identify those with a greater short-term improvement in maximal functional capacity after stopping β-blocker treatment.
Study context
- Population
- Stable heart failure with preserved ejection fraction (HFpEF) (NYHA II–III) on β-blocker with chronotropic incompetencecrossover
- Participants
- 52 participants
- Comparison
- β-blocker withdrawal vs continuation
- Primary endpoint
- Association between β-blocker withdrawal and short-term change in % predicted peak VO2 across iLVEDV, iLVESV and left ventricular ejection fraction (LVEF)
- Follow-up
- 2 weeks
Methodological detailspost hoc, crossover, investigator-blinded, multicentre
- Post hoc
- Crossover
- Investigator-blinded
- Multicentre
Primary result
As reported in the abstract
Change in % predicted peak VO2 after β-blocker withdrawal, across iLVESV
Withdrawal differentially associated with change in % peak VO2 across indexed left ventricular systolic volumes (iLVESV); greater benefit with lower iLVESV
P for interaction = .02
Further findings
| Outcome | Median increase (bpm) (95% CI) | P value | |
|---|---|---|---|
| Peak HR after stopping β-blocker treatment | 30 (25–35) | P < 0.001 | |
| −2002040Difference, bpm (linear scale) |
Original publication
β-Blocker Withdrawal and Functional Capacity Improvement in Patients With Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. Published 1 April 2024. doi:10.
Summarised from the published abstract; every number is checked against it